3D Systems Corporation — Q1 2024 Form 10-Q
Period: Three months ended March 31, 2024. The report was signed and filed August 20, 2024, well after the quarter ended. Unless otherwise noted, amounts are in U.S. dollars; financial amounts below are in millions.
Business context
3D Systems sells 3D printers, materials, software and related services through Healthcare Solutions and Industrial Solutions. Results are affected by the timing and concentration of large printer orders. One customer represented 16.3% of quarterly revenue, up from 13.5% a year earlier.
Financial results and liquidity
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | $102.9 | $121.2 |
| Gross profit / margin | $40.9 / 39.8% | $47.1 / 38.8% |
| Operating loss | $(39.9) | $(33.4) |
| Net loss attributable to 3D Systems | $(16.0) | $(29.4) |
| Basic and diluted loss per share | $(0.12) | $(0.23) |
| Adjusted EBITDA | $(20.1) | $(10.1) |
| Operating cash flow | $(25.5) | $(27.7) |
Revenue fell 15.1%, primarily because product revenue declined 24.1% to $64.1 million as printer sales weakened; services revenue rose 5.4% to $38.9 million. Gross margin improved by 1.0 percentage point, reflecting stronger services margins, while product margin fell to 38.2% from 40.9%, including higher inventory-reserve and write-off expense. The net loss narrowed largely because of a $21.5 million gain on debt extinguishment; operating loss widened and Adjusted EBITDA deteriorated.
Healthcare Solutions revenue was $45.4 million, down 6.8%, and segment Adjusted EBITDA was $3.7 million versus $5.1 million. Industrial Solutions revenue was $57.5 million, down 20.7%, and segment Adjusted EBITDA was $2.1 million versus $6.9 million.
Cash and cash equivalents were $212.0 million at March 31, down $119.5 million from year-end. The quarter used $25.5 million in operating cash and $3.2 million for capital expenditures; financing cash use was $89.2 million, primarily reflecting the debt repurchase. The company repurchased and retired $110.5 million principal amount of its 0% convertible notes for $87.2 million, including transaction expenses. Remaining principal was $214.4 million, due November 2026; carrying value was $211.1 million. Cash exceeded current liabilities of $145.9 million at quarter-end.
Changes, outlook and significant matters
- Revenue drivers: Product sales were pressured by lower printer volumes, including limited expected printer sales to a key dental customer for the rest of 2024, fewer large printer arrangements than in the prior-year quarter, and reduced kidney and liver research activity. Materials sales to the dental customer recovered, and services revenue increased.
- Restructuring: The company said metal-printer in-sourcing was substantially complete. Headcount actions were expected to be substantially complete in Q2 2024; facility exits and relocation work were to continue during 2024. Management estimated total headcount-reduction costs of $9–$10 million and projected annualized savings of $45–$55 million upon completion. Facility-exit costs or impairment charges may still arise.
- Liquidity outlook: Management said available cash and other liquidity sources should meet foreseeable requirements and cash needs for the next 12 months. No specific revenue or earnings guidance is provided in the filing. Longer-term cash needs depend partly on profitability and working-capital management.
- Convertible-note filing defaults: The company disclosed that late filing of its 2023 Form 10-K and this 10-Q triggered defaults under the note indenture after quarter-end. The 10-K was filed August 13, 2024, curing the first default; the company expected delivery of this 10-Q to the trustee to cure the remaining default. The filing states no special interest had been incurred and holders had taken no other action. The company was compliant as of March 31, 2024.
- Controls and filing timeliness: Management concluded disclosure controls were ineffective as of March 31 because of material weaknesses previously reported in the 2023 Form 10-K. The filing’s cover page also indicates the company had not filed all required reports on time during the preceding 12 months.
- Volumetric earnout dispute: Four of seven potential milestones, representing $180 million of a possible $355 million earnout, had been terminated before quarter-end. After key Volumetric employees resigned in April, the company said the remaining $175 million was no longer eligible to be earned; former owners and employees disputed the company’s position. A $1.5 million proposed settlement was accrued in Q1, rejected by the other parties in July, and mediation remained ongoing as of August 20. The filing states no reasonable estimate of potential liability for the dispute.
- Other developments and exposures: The company sold the dental-focused portion of Oqton MOS in May for a de minimis amount and continued evaluating alternatives for the remaining business. It invested a further $2.45 million in NAMI in May. The SEC investigation remained ongoing; a separate derivative-action settlement was subject to final court approval. A Brazilian subsidiary faced a contractor claim of approximately $0.8 million, which the company considers without merit.
- Other commitments: Purchase commitments totaled $20.9 million, with about $10.5 million due within 12 months. Operating and finance lease obligations, including interest, totaled $103.9 million. A $2.9 million balance remained recorded for the government export-control settlement, expected to be due by February 2025.
Important facts for investors to verify
- Whether filing the 10-Q with the trustee completed the cure of the remaining convertible-note indenture default, and whether any further compliance issues or holder actions arose.
- Progress in remediating the disclosed material weaknesses and the implications of the delayed 10-K and 10-Q filings.
- Whether the projected restructuring savings are achieved, and the cash costs or impairment charges associated with facility exits.
- Developments in the Volumetric mediation and the potential financial exposure; the disputed earnout amount is substantial, while the filing provides no estimable liability range.
- Whether revenue, operating cash flow and Adjusted EBITDA stabilize, especially given lower printer demand, customer concentration and the expected limited printer sales to the key dental customer.